<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190701044062N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-07-14</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of Sodium Pentaborate In Anal fissure</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of Sodium Pentaborate Topical Ointment on Anal fissure symptoms and treatment</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-09-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>140</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52206</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: ratio of 2 for sample size in intervention group to placebo group was considered and 129 patients (intervention group 86 cases, placebo group 43 cases) were needed to give a 80% chance of finding a 25% difference in healing between placebo and GTN at the 5% level. This number was increased by 10% to consider attrition or incomplete data. Finally, 140 cases (90 in intervention and 50 in placebo group) were recruited, Randomization description: The block randomization method will be used to assign patients to the intervention and control groups with the ratio of 2 for sample size in intervention group to placebo group. The size of the blocks is 6. ( Due to the difficulty in patient recruitment, we considered ratio of 2:1 for sample size in intervention group to placebo group to have more patients in intervention group). Randomization was performed using https://www.sealedenvelope.com/simple-randomiser/v1/lists [Accessed 11 Jul 2021].
Allocation concealment will be done using matte sealed envelopes, Blinding description: A gel that has an active ingredient in boron with a gel of placebo is completely identical in terms of the shape and size of the container, and the gels themselves do not differ in terms of odor and color, and are completely indistinguishable. (This action was taken by the pharmaceutical company). 
All ointments were either transparent and gelatinous and put in identical tubes by staff not involved further in the trial. Identical tubes were labeled as A and B.
When the physician saw chronic anal fissure on anal examination and the patient has inclusion criteria of the study gave patients A code and B code tubes, respectively. In some hospitals, active molecules were put in A coded tube, and some hospitals in B coded tubes. The randomization codes remained in the pharmaceutical company staff who prepared the drug during the trial and was not available to the investigators. After collecting the data and completing the data analysis stage, the nature of the codes related to the groups will be revealed by the liaison person in the pharmaceutical company.
The important point is that the patient is told that the gel used for the patient may be medication or medication. In blinding, the physician, patient, data analyzer, and researcher will be blind.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Anal fissure.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Topical ointment of 3% sodium pentaborate, which is made under GLP and GMP conditions at Yeditpe University in Turkey and is applied to the wound for 14 days (2 weeks) twice a day in the size of a fingertip. The patient is taught for 15 to 30 minutes by an experienced and trained expert. Intervention 2: Control group: These are the group that take placebo ointment that has no therapeutic properties. It is worth mentioning that the participants in this project are patients with chronic anal fissure who have not previously responded to routine treatment (increased consumption of dietary fiber and nifedipine ointment) and for this reason, placebo was used for the control group. We remind you that according to the inclusion criteria, patients should not have used any topical anal drug for at least the last 7 days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data, which includes information about the main outcome and results, will be shared.

When:
available from April 2021

To whom:
University researchers and professors

Conditions:
The data will be available to researchers and university professors for the studies of the meta - analysis.

Where to obtain:
Email: niloofarafshin1375@gmail.com
نیلوفر افشین

How to obtain:
Request via email: niloofarafshin1375@gmail.com
As soon as possible

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Manouchehr Khoshbaten</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166/15731</zip>
        <telephone>+98 41 3335 9680</telephone>
        <email>mkhoshbaten@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Manouchehr Khoshbaten</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166/15731</zip>
        <telephone>+98 41 3337 2088</telephone>
        <email>mkhoshbaten@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Chronic anal fissure that is detected in the perineal area by direct observation or rigid anoscopy or flexible colonoscopy.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Existence of any perineal complications including dermatitis, wart, condyloma, hemorrhoids, fistula, anal abscess
2. Proven Crohn's disease
3. Existence of lateral fissure
4. Patients with sodium pentaborate allergy
5. Pregnancy or breastfeeding
6. Patients with a history of serious cardiovascular, hepatic, renal and blood diseases
7. Taking any topical anal medication during the last 7 days
8. Prohibition of topical use of sodium pentaborate
being under the age of 18</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K60.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Anal fissure, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Topical ointment of 3% sodium pentaborate, which is made under GLP and GMP conditions at Yeditpe University in Turkey and is applied to the wound for 14 days (2 weeks) twice a day in the size of a fingertip. The patient is taught for 15 to 30 minutes by an experienced and trained expert.</i_keyword>
      <i_keyword>Control group: These are the group that take placebo ointment that has no therapeutic properties. It is worth mentioning that the participants in this project are patients with chronic anal fissure who have not previously responded to routine treatment (increased consumption of dietary fiber and nifedipine ointment) and for this reason, placebo was used for the control group. We remind you that according to the inclusion criteria, patients should not have used any topical anal drug for at least the last 7 days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anal itching. Timepoint: At the beginning of the study (before the intervention) and 14 days (2 weeks) after starting the ointment. Method of measurement: Ask the patient.</prim_outcome>
      <prim_outcome>Anal bleeding. Timepoint: At the beginning of the study (before the intervention) and 14 days (2 weeks) after starting the ointment. Method of measurement: Ask the patient, inspection of anus and digital rectal examination.</prim_outcome>
      <prim_outcome>Anal pain at rest. Timepoint: At the beginning of the study (before the intervention) and 14 days (2 weeks) after starting the ointment. Method of measurement: Ask the patient.</prim_outcome>
      <prim_outcome>Anal pain during defecation. Timepoint: At the beginning of the study (before the intervention) and 14 days (2 weeks) after starting the ointment. Method of measurement: Ask the patient.</prim_outcome>
      <prim_outcome>Bleeding from the fissure during the examination. Timepoint: At the beginning of the study (before the intervention) and 14 days (2 weeks) after starting the ointment. Method of measurement: Inspection of anus and digital rectal examination.</prim_outcome>
      <prim_outcome>Pain at the Fissure site during the examination. Timepoint: At the beginning of the study (before the intervention) and 14 days (2 weeks) after starting the ointment. Method of measurement: Ask the patient, inspection of anus and digital rectal examination.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Anal pain during defecation. Timepoint: At the beginning of the study (before the intervention) and 14 days (2 weeks) after starting the ointment. Method of measurement: Ask the patient.</sec_outcome>
      <sec_outcome>Feeling of a mass around the anus. Timepoint: At the beginning of the study (before the intervention) and 14 days (2 weeks) after starting the ointment. Method of measurement: Ask the patient.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-08-10</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Central Office of Tabriz University of Medical Sciences Tabriz -Golghast St.- Azadi St. Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
